 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ISB 1442 / Glenmark
Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6159;
P1/2
The observed clinical CRS events were moderate and potentially related to macrophage activation following ISB 1442 administration. Updated clinical, biomarker and PK data will be presented for this ongoing study.
- |||| ISB 1442 / Glenmark
FDA event, Orphan drug: FDA Grants Orphan Drug Designation to #ISB1442 for Relapsed/Refractory Multiple Myeloma https://t.co/hwfJjtjMlm 🔷FIH https://t.co/PtSoS5qrdb 🔶Ichnos pipeline https://t.co/geAPVx3Ji8 #バイパラトピック抗体 (Twitter) - Mar 28, 2023
- ISB 1442 / Glenmark
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6398;
P1/2
Hence, an enhanced CD38 targeted therapy that unleashes the innate immune cell mediated tumor killing potential and overcomes daratumumab resistance mechanisms may present a unique opportunity to treat MM...Due to low-affinity binding to CD47, ISB 1442 engages CD47 efficiently only upon CD38 binding (avidity-induced binding), thereby reducing the potential for on-target, off-tumor effects, and it does not cause any detectable RBC depletion in vitro compared to magrolimab (Figure 2)...The study is currently open for enrollment. Clinicaltrials.gov identifier: NCT05427812.
- ISB 1442 / Glenmark
Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4206;
P2
In summary, these data support the clinical development of 1442 in AML and T-ALL. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to have antitumor activity in AML and T-ALL patients in a single antibody relative to anti-CD38 or anti-CD47 monoclonal antibodies as well as their combination.
- ||| ISB 1442 / Glenmark
Enrollment open: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 14, 2022
P1/2, N=121, Recruiting, Sponsor: Ichnos Sciences SA
Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to have antitumor activity in AML and T-ALL patients in a single antibody relative to anti-CD38 or anti-CD47 monoclonal antibodies as well as their combination. Not yet recruiting --> Recruiting
- ISB 1442 / Glenmark
ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematological malignancies () - Jul 8, 2022 - Abstract #ITOC2022ITOC_62;
Conclusions We report a novel approach for the treatment for CD38 positive hematologic malignancies by co-targeting CD38 and CD47 using a first in class multispecific antibody. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to enhance antitumor activity in patients relative to anti-CD38 mAbs by overcoming primary and acquired tumor escape mechanisms of resistance.
- |||| ISB 1442 / Glenmark
New P1/2 trial: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 22, 2022
P1/2, N=121, Not yet recruiting, Sponsor: Ichnos Sciences SA
- ISB 1442 / Glenmark
ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES () - May 13, 2022 - Abstract #EHA2022EHA_1951;
Conclusion In summary, we report a novel approach for the treatment for CD38 positive hematologic malignancies by co-targeting CD38 and CD47 using a first in class multispecific antibody. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to enhance antitumor activity in patients relative to anti-CD38 mAbs by overcoming primary and acquired tumor escape mechanisms of resistance.
- ISB 1442 / Glenmark
ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematologic malignancies. () - May 9, 2022 - Abstract #CIMT2022CIMT_164;
In summary, we report a novel approach for the treatment of CD38 positive hematologic malignancies by co-targeting CD38 and CD47with a single agent. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to enhance antitumor activity in patients relative to anti-CD38 mAbs by overcoming primary and acquired tumor escape mechanisms of resistance.
- Darzalex (daratumumab) / J&J, ISB 1342 / Glenmark, magrolimab (GS-4721) / Ono Pharma, Gilead
A multispecific antibody platform for optimal engineering of multiple myelomaimmunotherapies. () - May 9, 2022 - Abstract #CIMT2022CIMT_156;
P1
In summary, we report two novel approaches for the treatment of MM using the BEAT technology to co-target either CD38 and CD3, or CD38 and CD47. The designs of ISB 1342 and ISB 1442 are anticipated to enhance antitumor activity in MM patients by overcoming primary and acquired mechanisms of resistance.
- ISB 1442 / Glenmark
"ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematologic malignancies" () - May 9, 2022 - Abstract #CIMT2022CIMT_60;
- ISB 1442 / Glenmark, Darzalex (daratumumab) / J&J
BEAT, a Plug-and-Play Platform for Engineering Novel Multi-Specific Antibodies Against Cancer (Ballroom C) - Apr 24, 2022 - Abstract #PEGS2022PEGS_593;
ISB 1442, a first-in-class 2+1 biparatopic BEAT® 2.0 bispecific (CD38xCD47) antibody, demonstrates higher potency and tumor growth inhibition preclinically relative to daratumumab. A Phase 1 study in hematologic malignancies is planned for mid-2022.
- ISB 1442 / Glenmark
Engineering ISB 1442, a First-in-Class 2+1 Biparatopic Multispecific Antibody that Targets both CD38 and CD47, as a Treatment for Relapsed/Refractory Multiple Myeloma and Other CD38-Positive Hematologic Malignancies () - Apr 24, 2022 - Abstract #PEGS2022PEGS_62;
- ISB 1442 / Glenmark
ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_4833;
In summary, we report a novel approach for the treatment for CD38+ cancers by co-targeting CD38 and CD47. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to enhance antitumor activity by overcoming known primary and acquired tumor escape mechanisms of resistance relative to daratumumab.
- || ISB 1442 / Ichnos Sciences
From ASH 2021 RT @UrviShahMD: ISB 1442 is a novel CD38 and CD47 biparatopic bispecific antibody and first in human study is expected to start in… https://t.co/4PZgOV6rFw (Twitter) - Dec 11, 2021
- |||| ISB 1442 / Ichnos Sciences
Clinical: Isb1442 cd38 and cd47 antibody looks like a really cool mechanism of action that may have important clinical role. #ASH2021 #mmsm (Twitter) - Dec 11, 2021
- ISB 1442 / Ichnos Sciences, Darzalex IV (daratumumab) / J&J
ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma (GWCC - Sidney Marcus Auditorium, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_1288;
In summary, we report a novel approach for the treatment for rrMM by co-targeting CD38 and CD47 using a 2+1 biparatopic bispecific antibody. Based on its unique design and multiple mechanisms of action, ISB 1442 is anticipated to enhance antitumor activity in rrMM patients relative to anti-CD38 mAbs by overcoming primary and acquired tumor escape mechanisms of resistance.